Qiming Venture Partners Research
Investment Thesis
Qiming Venture Partners (启明创投) is a leading Asia-based (predominantly China-focused, with a US presence) venture capital firm founded in 2006 by Duane Kuang and Gary Rieschel. The firm's stated mission, captured in its tagline "以智启众 以勤得明" ("Enlightening the many through wisdom, achieving clarity through diligence"), is to find and back great enterprises facing the future that bring long-term value to humanity and society. Qiming positions itself as more than a capital provider: it emphasizes unreserved industry resource connections, trust-based relationships with entrepreneurs, and a dedicated portfolio-services ecosystem covering team-building, strategic decision support, and advisory access.
Sector Focus
Qiming concentrates on two core verticals:
- Technology (TMT): artificial intelligence, robotics, autonomous driving and X-by-wire/chassis systems, semiconductors, enterprise software, consumer internet, and mobile internet.
- Healthcare & Life Sciences: innovative drug R&D (including mRNA and biologics platforms), diagnostics, gene sequencing, medical devices, and digital health.
Cross-cutting interest in AI/ML shows up across both verticals — from AI-driven drug discovery to frontier-model infrastructure and AI hardware plays.
Stage Focus
Qiming invests across the full lifecycle, from early financing through public markets, but roughly 70% of check volume concentrates in Series A and Series B rounds. The firm also participates selectively in Pre-IPO/growth rounds and continues to support portfolio companies through IPO and M&A events.
Check Size
Publicly reported deal data puts typical checks in the $500K–$34M range, with reported averages around $16.9M at seed, $23.9M at Series A, and $34M at Series B. Later-stage/growth checks (Pre-IPO co-leads) have run as large as $50M+ in aggregate round size alongside co-investors.
Lead Tendency
Qiming both leads and co-leads rounds depending on stage and syndicate composition — e.g., it led NASN Intelligent Tech's Series A as a co-lead in 2018, co-led Minghui Pharmaceutical's $131M Pre-IPO round in 2025, and led Noitom Robotics' Pre-A+ round in December 2025.
Recent Activity
Qiming has been highly active through 2025 and into 2026, with a strong run of portfolio IPOs:
- August 2026: Portfolio companies NASN Intelligent Tech (HKEX: 02261.HK) and Attovia Therapeutics (Nasdaq: ATTO) both went public within the same week — Qiming's ninth and tenth 2026 IPO exits by that point.
- May 2026: Managing Partner Alex Zhou named to the 2026 Forbes Midas List (debut, #80), with four of his portfolio companies (Biren Technology, Zhipu AI, Axera Semiconductor, Viewtrix Technology) completing public listings in the first five months of 2026 alone.
- August 2025: Co-led Minghui Pharmaceutical's $131M Pre-IPO financing (oncology/PD-1/VEGF bispecific antibody pipeline) alongside OrbiMed.
- December 2025: Led Noitom Robotics' Pre-A+ round with participation from 5Y Capital and Legend Capital.
Overall, Qiming reports ~26 investments in 2025 and 13 in the first four months of 2026, consistent with an average of ~25 new investments per year over the trailing decade — indicative of an actively deploying fund across its current fund family.
Portfolio Highlights
Qiming reports 580+ portfolio companies (as of August 2024), 70+ IPOs, and 140+ M&A/other exits. Marquee names include Xiaomi (HKEX-listed smartphone/IoT giant), Meituan (life-services super-app), Bilibili (Nasdaq-listed video community), Zhihu (NYSE-listed Q&A platform), Zai Lab (biopharma), and Hesai Technology (Nasdaq-listed autonomous-vehicle lidar). Recent public debuts include Attovia Therapeutics, NASN Intelligent Tech, LongBio Pharma, and Viewtrix Technology.
Team
Qiming is a multi-partner firm with a broad investment team spanning Beijing, Shanghai, Shenzhen, Hong Kong, and a US presence:
- Duane Kuang (邝子平) — Founding Managing Partner
- Gary Rieschel — Founding Managing Partner
- Hu Xubo (胡旭波) — Managing Partner
- Zhou Zhifeng (周志峰) — Managing Partner
- Alex Zhou (张奥) — Managing Partner; 2026 Forbes Midas List debut (#80); focuses on frontier tech/AI
- Chen Kan (陈侃) — Partner
- Li Shuxian (李淑娴) — Partner & Group Chief Operating Officer
- Yu Jia (于佳) — Partner & RMB Fund General Manager
- Zhang Yi (张毅) — Partner, China COO & Chief Legal Officer
Below the partner level, Qiming maintains a large bench of Executive Directors, Vice Presidents, and Investment Managers covering sector-specific diligence.
Decision Process
With multiple managing partners and partners each carrying deal responsibility across geographies and sectors, Qiming operates as a partnership-style investment process rather than a single decision-maker model; larger Pre-IPO/growth checks appear to involve board-level partner engagement (e.g., board seats taken alongside co-lead OrbiMed in the Minghui Pharmaceutical round).
Founder Preferences
Public materials don't specify a codified founder profile, but portfolio composition skews toward deep technical/scientific founders in hard-tech and biotech (e.g., drug-discovery platform companies, autonomous-vehicle hardware, semiconductor and AI infrastructure builders) alongside consumer-internet operators at scale (Xiaomi, Meituan, Bilibili, Zhihu).
Geographic Focus
Primarily Greater China (Beijing, Shanghai, Shenzhen, Hong Kong), with a dedicated US entity (Qiming Venture Partners USA) extending reach into US-based biotech and technology investments (e.g., Attovia Therapeutics, Alamar Biosciences).
AUM and Fund Status
Qiming reports $9.5B in AUM across 18 funds (11 USD-denominated, 7 RMB-denominated), including Fund VII, which closed at $1.2B in November 2020 after an initial $1.1B close earlier that year. The firm's continued high-cadence investment pace and string of 2025–2026 IPO exits indicate an actively deploying, healthy fund cycle.